Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Reports Soaring Product Sales in Q3 as Revenue More Than Doubles

NEW YORK, Nov. 3 (GenomeWeb News) - Cepheid's revenues more than doubled during the third quarter, driven by increased product sales, the company reported yesterday. However, this surge was almost eaten up by soaring costs of product sales, resulting in a slightly reduced net loss.


Cepheid's revenues for the quarter ended Sept. 30 totaled $14.1 million, up from $5.4 million during the same period last year. This increase was driven largely by sales related to the United States Postal Service Bio-hazard Detection System, and, to a lesser extent, by Life Sciences and Clinical Genetic Assessment products.


R&D expenses increased slightly, to $4 million from $3.8 million during the year-ago quarter.


The company's net loss for the quarter amounted to $2.9 million, or $.07 per share, down from $3.9 million, or $.11 per share, during the same quarter last year.


As of Sept. 30, Cepheid had $58.2 million in cash and cash equivalents.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.